Your browser doesn't support javascript.
loading
Psychometric evaluation of clinician- and caregiver-reported clinical severity assessments for individuals with CDKL5 deficiency disorder.
Saldaris, Jacinta M; Jacoby, Peter; Downs, Jenny; Marsh, Eric D; Leonard, Helen; Pestana-Knight, Elia; Rajaraman, Rajsekar; Weisenberg, Judith; Suter, Bernhard; Olson, Heather E; Price, Dana; Hong, William; Prange, Erin; Benke, Tim A; Demarest, Scott.
Affiliation
  • Saldaris JM; Telethon Kids Institute, Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia.
  • Jacoby P; Telethon Kids Institute, Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia.
  • Downs J; Telethon Kids Institute, Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia.
  • Marsh ED; Curtin School of Allied Health, Curtin University, Perth, Western Australia, Australia.
  • Leonard H; Departments of Neurology and Pediatrics, Division of Child Neurology and University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Pestana-Knight E; Telethon Kids Institute, Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia.
  • Rajaraman R; Cleveland Clinic, Neurological Institute, Cleveland, Ohio, USA.
  • Weisenberg J; UCLA Mattel Children's Hospital, Los Angeles, California, USA.
  • Suter B; St. Louis Children's Hospital and Washington University School of Medicine, St. Louis, Missouri, USA.
  • Olson HE; Department of Pediatrics & Neurology, Baylor College of Medicine, Houston, Texas, USA.
  • Price D; Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Hong W; NYU Langone Health and Department of Neurology, New York University, New York City, New York, USA.
  • Prange E; Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Benke TA; Departments of Neurology and Pediatrics, Division of Child Neurology and University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Demarest S; Departments of Pediatrics, Neurology and Pharmacology, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.
Epilepsia ; 2024 Aug 27.
Article in En | MEDLINE | ID: mdl-39190322
ABSTRACT

OBJECTIVE:

The CDKL5 Clinical Severity Assessment (CCSA) is a comprehensive, content-validated measurement tool capturing the diverse challenges of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), a genetically caused developmental epileptic encephalopathy (DEE). The CCSA is divided into clinician-reported (CCSA-Clinician) and caregiver-reported (CCSA-Caregiver) assessments. The aim of this study was to evaluate the factor structure of these measures through confirmatory factor analysis (CFA) and evaluate their validity and reliability.

METHODS:

Participants were recruited from the International CDKL5 Clinical Research Network to take part in an in-clinic CCSA-Clinician evaluation (n = 148) and/or complete the CCSA-Caregiver questionnaire (n = 198). CFA was used to determine domains, and factor loadings and validity were assessed. For the CCSA-Clinician, inter-rater reliability was assessed by nine CDD experienced clinicians via 14 pre-recorded evaluations. Eight clinicians re-viewed and re-scored the videos after 4 weeks to evaluate intra-rater reliability. The CCSA-Caregiver was completed on a second occasion by 34 caregivers after 2-4 weeks to assess test-retest reliability.

RESULTS:

CFA resulted in three domains for the CCSA-Clinician (motor and movement, communication, vision) and four domains for the CCSA-Caregiver (seizures, behavior, alertness, feeding), with good item loadings across both measures. Structural statistics, internal consistency, discriminant validity, and reliability were satisfactory for both measures, and scores were consistent between known groups.

SIGNIFICANCE:

This study provides strong evidence that the CCSA measures are suitable to assess the clinical severity of individuals with CDD, supporting their use in clinical trials. Further evaluation of responsiveness to change in a longitudinal assessment is planned. Use may also be appropriate in similar DEEs but would require validation in those populations.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Epilepsia Year: 2024 Type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Epilepsia Year: 2024 Type: Article Affiliation country: Australia